Company: ARTL
Filing Date: 2025-10-01
Form Type: 8-K
Source: 0001640334-25-001766
Chunk: 1

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-01
Form: 8-K
Item: Item 1.01
Chunk 1
---
 working capital and general corporate purposes. In addition, the Company may use the net proceeds from the Offering for investments in products or technologies that are complementary to its business.

The Underwriting Agreement contains customary representations, warranties and covenants made by the Company. It also provides for customary indemnification by each of the Company and the Underwriter, severally and not jointly, for losses or damages arising out of or in connection with the Offering. In addition, pursuant to the terms of the Underwriting Agreement, each of the Company’s directors and executive officers have entered into lock-up agreements that generally prohibit, without the written consent of the Underwriter, the sale, transfer or other disposition of securities of the Company until 30 days following the date of the Underwriting Agreement. The Company has also agreed for a period of 30 days from the Closing Date, not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company, including effecting or entering into an agreement to effect any issuance by the Company involving a Variable Rate Transaction (as defined in the Underwriting Agreement), without the written consent of the Underwriter.

We also granted the Underwriter a right of first refusal to act as sole and exclusive investment banker, book-runner, financial advisor, underwriter and/or placement agent, for each and every future public and private equity and debt offering, including all equity linked financings, for the Company, or any successor to or any subsidiary of the Company, until December 31, 2025.

The Offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-273153) previously filed with the Securities and Exchange Commission (the “ SEC”) on July 6, 2023, and declared effective on July 14, 2023, a preliminary prospectus relating to the Offering filed with the SEC on September 30, 2025, and a final prospectus supplement relating to the Offering filed with the SEC on October 1, 2025.

The foregoing descriptions of the Underwriting Agreement and Pre-funded Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, which are filed as Exhibits 1.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

A copy of the legal opinion and